NurExone Biologic is a biopharmaceutical company focused on developing an exosome-based therapy platform aimed at regenerating damaged tissue and treating central nervous system injuries. Its flagship candidate, ExoPTEN, is being advanced toward clinical application as part of a broader proprietary pipeline. The company operates between Israel and Canada and has recently gained international attention, being named a finalist for both the Prix Galien Bridges Awards and the Falling Walls ‘Science Breakthroughs of the Year’ competition. To fuel its R&D, NurExone secured more than C$3.18 million in fresh capital through warrant exercises, bolstering its balance sheet and working capital. Management states that the new funds will primarily support continued pre-clinical and clinical development of its exosome platform and general corporate purposes. No specific operating metrics such as revenue or user numbers have been disclosed. The company relies on private placements and warrant-related financings to fund its growth trajectory.

Total raised

$2M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2025